fludarabine,cyclophosphamide,brexucabtagene autoleucel,etoposide,rituximab,doxorubicin,axicabtagene ciloleucel,vincristine,lisocabtagene maraleucel,prednisone
bms,gilead
['dlbcl', 'transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'zuma1', 'zuma 7', 'zuma12', 'zuma23', 'zuma2']
dlbcl ed session 4 topics in cart:
-some lessons learned from cart 3l
-os superior to soc in 2l (zuma 7); transform (abramson, ash 2022) 2l cr 74%, 3l cr 53%
-cart in 1l high-risk patients: zuma12, zuma23
- efficacy and safety in cns involvement 
Hematologist MD, PhD @ClinicaNavarra @CancerCCUN @unav #lymphoma #CLL #CART #CardioOnc Opinions are my own